Cipla reported its highest-ever annual revenue of over ₹28,000 crore for FY26. The company's India business grew 9% to ₹12,500 crore. Cipla recommended a final dividend of ₹13 per share.
Cipla's FY26 Revenue Surges Past ₹28,000 Crore, India Business Leads Growth
Cipla's consolidated revenue for FY 2026 reached an all-time high of over ₹28,000 crore. The company's India business also achieved a milestone, crossing ₹12,500 crore with 9% growth. Cipla reported an EBITDA margin of 21% and a PAT margin of 13.8%. The company's cash reserves stand strong at ₹11,000 crore. The Board has recommended a final dividend of ₹13 per equity share for FY 2026.
What just happened
Cipla announced its fiscal year 2026 financial results, highlighting record-breaking consolidated revenue and significant growth in its domestic operations. The company also proposed a new statutory auditor and a final dividend payment to shareholders.
Why this matters
This performance indicates Cipla's continued market strength and financial robustness. The record revenue and healthy India business growth are positive signals for investors, while the proposed dividend offers direct returns. The focus on R&D and complex products signals a future-oriented strategy.
The backstory
Cipla has been navigating margin pressures, particularly in the US market due to generic drug pricing and the expiry of key drug exclusivity. The company has been investing in R&D and diversifying its product pipeline to counter these challenges and maintain long-term growth.
What changes now
The company will appoint M/s B S R & Co. LLP as its new statutory auditor for a five-year term. Shareholders will receive a final dividend of ₹13 per share, subject to approval. The company plans to file 40-50 new products in the US over three years.
Risks to watch
Persistent pricing pressure in the US generic market and ongoing supply chain challenges remain key risks. Cipla is managing these through higher inventory levels and a strategic shift to complex, high-barrier products.
Peer comparison
Cipla's focus on complex generics and innovation aligns with broader industry trends aimed at countering pricing pressures. Its strong performance in the Indian market positions it well against domestic and international peers operating in similar segments.
Context metrics (time-bound)
- FY 2026 Consolidated Revenue: ₹28,000+ crore
- India Business Revenue: ₹12,500 crore (9% growth)
- R&D Expenditure: ₹1,974 crore (7% of revenue)
- Cash Position: ₹11,000 crore
- Proposed Final Dividend: ₹13 per equity share
What to track next
Investors will be watching the execution of Cipla's US product filing strategy and its success in introducing complex generics. Monitoring supply chain stability and the resolution of any ongoing regulatory audits will also be crucial.